La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Harmony Biosciences Holdings Résultats passés
Passé contrôle des critères 3/6
Harmony Biosciences Holdings has been growing earnings at an average annual rate of 73%, while the Pharmaceuticals industry saw earnings declining at 0.2% annually. Revenues have been growing at an average rate of 31.7% per year. Harmony Biosciences Holdings's return on equity is 21.4%, and it has net margins of 17.5%.
Informations clés
73.0%
Taux de croissance des bénéfices
92.8%
Taux de croissance du BPA
| Pharmaceuticals Croissance de l'industrie | 6.0% |
| Taux de croissance des recettes | 31.7% |
| Rendement des fonds propres | 21.4% |
| Marge nette | 17.5% |
| Dernière mise à jour des bénéfices | 30 Jun 2024 |
Mises à jour récentes des performances passées
Recent updates
Harmony Biosciences: Advancing An Expanded Pipeline
Aug 15Harmony Biosciences Holdings (NASDAQ:HRMY) Has A Rock Solid Balance Sheet
Jul 15
Investors Holding Back On Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)
Jun 07Harmony Biosciences Holdings, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
May 03These 4 Measures Indicate That Harmony Biosciences Holdings (NASDAQ:HRMY) Is Using Debt Safely
Apr 04Market Cool On Harmony Biosciences Holdings, Inc.'s (NASDAQ:HRMY) Earnings
Feb 09Fewer Investors Than Expected Jumping On Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)
Mar 21Does Harmony Biosciences Holdings (NASDAQ:HRMY) Deserve A Spot On Your Watchlist?
Dec 01Harmony Biosciences: In Harmony
Sep 23We Ran A Stock Scan For Earnings Growth And Harmony Biosciences Holdings (NASDAQ:HRMY) Passed With Ease
Aug 05Harmony Biosciences Non-GAAP EPS of $0.57 misses by $0.06, revenue of $107M beats by $6.25M
Aug 02Harmony Biosciences: Steady Revenue Generator Looking For A Future
May 26Harmony Biosciences: Strong Growth At A Reasonable Price
Mar 04Our First Look At Harmony Biosciences
Nov 04Ventilation des recettes et des dépenses
Comment Harmony Biosciences Holdings gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
| Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
|---|---|---|---|---|
| 30 Jun 24 | 656 | 115 | 209 | 134 |
| 31 Mar 24 | 618 | 138 | 201 | 85 |
| 31 Dec 23 | 582 | 129 | 193 | 76 |
| 30 Sep 23 | 542 | 151 | 182 | 56 |
| 30 Jun 23 | 499 | 200 | 177 | 79 |
| 31 Mar 23 | 472 | 189 | 172 | 77 |
| 31 Dec 22 | 438 | 181 | 163 | 71 |
| 30 Sep 22 | 401 | 156 | 157 | 68 |
| 30 Jun 22 | 364 | 58 | 148 | 39 |
| 31 Mar 22 | 331 | 49 | 137 | 33 |
| 31 Dec 21 | 305 | 35 | 132 | 30 |
| 30 Sep 21 | 271 | 12 | 126 | 31 |
| 30 Jun 21 | 235 | 17 | 115 | 23 |
| 31 Mar 21 | 200 | -7 | 103 | 21 |
| 31 Dec 20 | 160 | -64 | 96 | 19 |
| 30 Sep 20 | 109 | -110 | 92 | 19 |
| 30 Jun 20 | 64 | -146 | 94 | 19 |
| 31 Mar 20 | 26 | -165 | 90 | 20 |
| 31 Dec 19 | 6 | -187 | 81 | 70 |
Des revenus de qualité: HRMY has high quality earnings.
Augmentation de la marge bénéficiaire: HRMY's current net profit margins (17.5%) are lower than last year (40.1%).
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: HRMY has become profitable over the past 5 years, growing earnings by 73% per year.
Accélération de la croissance: HRMY's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Bénéfices par rapport au secteur d'activité: HRMY had negative earnings growth (-42.6%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (13%).
Rendement des fonds propres
ROE élevé: HRMY's Return on Equity (21.4%) is considered high.